latest news releases from the newsroom
Discovery Laboratories, Inc.
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric Academic Societies' Annual Meeting
WARRINGTON, Pa., May 8, 2007 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that results from its previously completed Phase 2 clinical trial of Surfaxin(r) (lucinactant intratracheal suspension) for the prevention and treatment of Bronchopulmonary Dysplasia (BPD) were selected and presented as a platform presentation at the Pediatric Academic Societies' (PAS) Annual Meeting in Toronto, Canada. Also presented at PAS were data regarding Discovery's novel aerosolized KL-4 surfactant, Aerosurf(tm) (lucinactant for inhalation). The Pediatric Academic Societies' annual meeting is internationally recognized as the largest, most relevant medical meeting dedicated to pediatric critical care research. These data were presented for the first time to the medical community.
Aquila Reports First Quarter 2007 Results
KANSAS CITY, Mo., May 8, 2007 (PRIME NEWSWIRE) -- Aquila, Inc. (NYSE:ILA) today reported a net loss of $24.3 million for the quarter ended March 31, 2007, or fully diluted per share loss of six cents, compared to a net loss of $1.1 million in 2006, or a fully diluted per share loss of less than one cent. Sales for the quarter were $444 million in 2007 versus $431 million in 2006.